Out-licensing: Tolerogenic Approach For Type I Diabetes

Latest: Watch here for details of new products and services.

About Us: Pharmalicensing - Partnering solutions for the life sciences
Our Products: Overview; Partnering Search; Company Profiling; Deal Negotiation; PL Intelligence; Reports; Comparison
PL Intelligence: Overview; Industry news; Deals review; Press releases; Articles
Case Studies: See what others think about our service
Newsletter: Partnering update; Key reports; Subscribe
Quick Links: Profile now; Register now; Profiled companies; Featured events; Industry news; PR Newswire; Jobs
Contact Pharmalicensing: Send an email; Call us: +44 1904 520460; Request a callback
RSS Feeds: Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd

Out-licensing
View

Tolerogenic approach for type I diabetes

A new method for prevention and cure of type 1 diabetes

Full description

A new method for prevention and/or cure of type 1 diabetes based on: 1° the intrathymic expression of IGF2 (Insulin-like growth factor 2) as the dominant gene of the insulin family; 2° the defect of Igf2 expression in the thymus of animal model of type 1 diabetes; and 3° the regulatory/tolerogenic profile of cytokine secretion induced by DQ8 presentation of IGF-2 B11-25 in cultures of PBMCs isolated from DQ8+ type 1 diabetic adolescents. Potential applications : Design of a novel type of tolerogenic (negative) vaccine to inhibit the development of the autoimmune response selective of insulin-secreting islet ß cells.

Patent information

Research collaboration for license agreement

Licensing contact

Dr Nicole Antheunis

Contact directly

Company details

University of Liège (ULg), Interface Entreprises-Université, Liege

The Interface Entreprises-Université is a multidisciplinary team committed to industry, which is responsible of the Liège University technology transfer (IP protection, licences, spinoff

View profile

Visit website

Related reports

Are you looking for reports related to this particular subject. Our Reports section is the best place to start.

Related items

Animal Intravascular Catheter

Micro Fine, Dry Powder Pulmonary Drug Delivery Technology Suite

A Battery of Genetic Biomarkers of Severe Outcome in Patients with Elevated Triglyceride Levels

Cannabidiol as a Future Drug against Diabetes

Unique advanced herbal product indicated for the treatment of ischaemic heart condition, diabetes, diabetic lesions and circulatory diseases as well.

Related categories

Industry sector: Biotechnology; Drug discovery; Biotechnology / Human therapeutics; Biotechnology / Other; Pharmaceutical; Pharmaceutical / Prescription
Therapeutic target: Metabolism / Diabetes type I; Metabolism; Other therapeutic

Clients in focus...

Get the Flash Player to see this rotator.

Press releases: Pharmalicensing current industry press releases.

Products:	Partnering Search	Company Profiling	Deal Negotiation	PL Intelligence	Reports	Comparision
In-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Out-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Companies:	Profiled companies	Industry Sector	Therapeutic Target	Geographic Location	Search	Add your company
Reports:	Biotechnology	Business Development	Management	Market & Sales	Medical Devices	Pharmaceuticals
Jobs:	Pharmaceutical jobs	Browse jobs	Search for jobs	Create your CV	Employer profiles	Post your jobs
Forums:	Talk to an expert	Industry Gossip	Business Development	What's new	Reports	Services
News:	Deals & Alliances	Development	Financial Results	Financings	Intellectual Property	Regulatory
Events:	Pharma events	Calendar	Organizers	Featured events	Search
Articles:	Business Development	Technologies	Events	Legal and regulatory	Therapeutic
Deals:	Industry Sector	Therapeutic Target	Deals Date	Search	Reports	Press releases
About us:	Our Audience	Case Studies	Newsletter	Careers	FAQ	Contact us